レボドパ・カルビドパ水和物 shortage — JP supply status & alternatives

レボドパ・カルビドパ水和物

—

In supply · Australia

メネシット配合錠２５０

In supply · 🇦🇺 Australia · short in🇯🇵 JP

In supply in Australia

Reading today’s signals…

✓ Can I substitute?

In supply

no shortage substitution needed

⇄ Best alternative

None listed

refer to prescriber

◷ Expected back

No estimate

No estimate provided

Product attributes reference data we hold

Controlled substance
Active ingredient (INN)	レボドパ・カルビドパ水和物
Brand names	メネシット配合錠２５０
Therapeutic category	Auto-created by Ministry of Health, Labour and Welfare — Drug Supply Status scraper

Patient information leaflet (PIL)	Not on file

Summary of product characteristics (SPC)	Not on file

Trade price 🇦🇺 Australia · awaiting price ingest

🇦🇺 AU

Ex-manufacturer

—

Dispensed (DPMQ)

—

Pack

—

Not yet captured for Australia

Official pricing isn’t on file for this market yet. PBS (Australia), NHS Drug Tariff (United Kingdom) and CMS NADAC (United States) feeds are prioritised; this panel populates automatically once the data lands.

Verified timeline regulator events

🇯🇵 1 July 2026

critical reported

🇯🇵 20 June 2026

critical reported

🇯🇵 18 June 2026

critical reported

🇯🇵 10 June 2026

critical reported

🇯🇵 8 June 2026

critical reported

🇯🇵 4 June 2026

critical reported

For health-professional reference only. Mederti aggregates shortage and substitution information from official regulatory sources. It is not clinical advice and data may be incomplete or delayed. Confirm any substitution or supply decision against the primary regulator source, the prescriber, and current clinical references (e.g. AMH) before acting. Terms.